Archer G L, Auger P, Doern G V, Ferraro M J, Fuchs P C, Jorgensen J H, Low D E, Murray P R, Reller L B, Stratton C W
Medical College of Virginia, Richmond.
Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):223-6. doi: 10.1016/0732-8893(93)90113-l.
To assess the potential clinical utility of RP 59500, 10 investigators from separate locations in the United States and Canada each tested approximately 200 current isolates of staphylococci (Staphylococcus aureus and coagulase-negative staphylococci) by a standard protocol. RP 59500 was highly active (MIC90 < or = 2 micrograms/ml) against all strains, including those that were resistant to oxacillin, ciprofloxacin, erythromycin, and spiramycin.
为评估RP 59500的潜在临床效用，来自美国和加拿大不同地点的10名研究人员各自按照标准方案对约200株当前的葡萄球菌分离株（金黄色葡萄球菌和凝固酶阴性葡萄球菌）进行了检测。RP 59500对所有菌株均具有高活性（MIC90≤2微克/毫升），包括那些对苯唑西林、环丙沙星、红霉素和螺旋霉素耐药的菌株。
